Zimmer and Anika expand Orthovisc deal:
This article was originally published in Clinica
Zimmer and Anika Therapeutics have extended their exclusive, multi-year distribution agreement for Orthovisc, an injectable product based on hyaluronic acid to restore the elasticity and viscosity of the synovial fluid. Under the new agreement, Zimmer will sell the product in Europe and Latin America. Anika will receive up to $3.5 million. The two companies' initial agreement covered the US, Canada and certain Asia-Pacific countries.
You may also be interested in...
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.